Solriamfetol

Summary

Solriamfetol (CHEMBL4297620) is an approved small molecule (ATC N06BA14) targeting SLC6A2 and SLC6A3; indicated across 5 conditions including attention deficit-hyperactivity disorder and obstructive sleep apnea syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06BA14
• Targets: 2 (SLC6A2, SLC6A3)
• Indications: 5 conditions
• Clinical trials: 23
• Chemistry: 194.23 Da · C10H14N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297620
Name	Solriamfetol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	10130337
ATC	N06BA14
Molecular formula	C10H14N2O2
Molecular weight	194.23
InChIKey	UCTRAOBQFUDCSR-SECBINFHSA-N

SMILES: C1=CC=C(C=C1)C[C@H](COC(=O)N)N

IUPAC name: [(2R)-2-amino-3-phenylpropyl] carbamate

Also known as: ADX-N-05, Jzp-110, JZP-110, R-228060, SKL-N-05, Solriamfetol, YKP-10A, SOLRIAMFETOL

Parent form; salt/anhydrous children: CHEMBL4297212

Patent coverage: 94 distinct patent families (385 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC6A2	NET	Inhibition	5.36	0.4%	P23975
SLC6A3	DAT	Inhibition	4.85	0.2%	Q01959

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): SLC6A2, SLC6A3.

Top Reactome pathways

14 total, by targets touching each:

Pathway	Targets	Genes
Disease	2	SLC6A2, SLC6A3
Transport of small molecules	2	SLC6A2, SLC6A3
R-HSA-425366	2	SLC6A2, SLC6A3
SLC-mediated transmembrane transport	2	SLC6A2, SLC6A3
SLC-mediated transport of neurotransmitters	2	SLC6A2, SLC6A3
SLC transporter disorders	2	SLC6A2, SLC6A3
Disorders of transmembrane transporters	2	SLC6A2, SLC6A3
Neurotransmitter clearance	1	SLC6A3
Transmission across Chemical Synapses	1	SLC6A3
Neuronal System	1	SLC6A3
Dopamine clearance from the synaptic cleft	1	SLC6A3
Defective neurotransmitter clearance by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Defective transport of neurotransmitters by SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)	1	SLC6A3

Dominant GO biological processes

GO term	Targets
neurotransmitter transport	2
amino acid transport	2
response to xenobiotic stimulus	2
obsolete monoamine transport	2
sodium ion transmembrane transport	2
dopamine uptake involved in synaptic transmission	2
norepinephrine uptake	2
transmembrane transport	2
chemical synaptic transmission	1
obsolete norepinephrine transport	1
response to pain	1
neuron cellular homeostasis	1
catecholamine uptake	1
neurotransmitter reuptake	1
chloride transmembrane transport	1

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	4	MONDO:0007743	EFO:0003888
obstructive sleep apnea syndrome	3	MONDO:0007147	EFO:0003918
narcolepsy	3	MONDO:0021107	MONDO:0021107
eating disorder	3	MONDO:0005451	EFO:0005203
hypersomnia	2	MONDO:0005466	EFO:0005246

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE3	11
PHASE2	7
PHASE4	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04602936	PHASE4	UNKNOWN	Solriamfetol in Binge Eating Disorder
NCT04788953	PHASE4	TERMINATED	Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder
NCT04789174	PHASE4	COMPLETED	Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
NCT05838430	PHASE4	COMPLETED	Solriamfetol and CBT-I in Patients With Insomnia Disorder
NCT06413433	PHASE3	RECRUITING	Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06568367	PHASE3	RECRUITING	Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06878976	PHASE3	ENROLLING_BY_INVITATION	Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
NCT07484217	PHASE3	RECRUITING	Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT02348593	PHASE3	COMPLETED	Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy
NCT02348606	PHASE3	COMPLETED	Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA
NCT02348619	PHASE3	COMPLETED	Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA
NCT02348632	PHASE3	COMPLETED	A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA
NCT04839562	PHASE2/PHASE3	COMPLETED	A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NCT05972044	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT06103825	PHASE3	COMPLETED	A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
NCT06360419	PHASE3	COMPLETED	Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
NCT06170970	PHASE2	RECRUITING	Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06404099	PHASE2	ACTIVE_NOT_RECRUITING	RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06590662	PHASE2	NOT_YET_RECRUITING	Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.
NCT02806895	PHASE2	COMPLETED	Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
NCT02806908	PHASE2	COMPLETED	Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
NCT03037203	PHASE2	COMPLETED	A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson’s Disease and Excessive Sleepiness
NCT06404086	PHASE2	COMPLETED	RECOVER-SLEEP: Platform Protocol

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

586 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
Idelalisib	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
Olodaterol	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	SLC6A2, SLC6A3
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AMINOCAPROIC ACID	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AMLODIPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AMODIAQUINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
ATOMOXETINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENOXINATE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENZIODARONE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BENZYL BENZOATE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BEXAROTENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BITHIONOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CANNABIDIOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CASPOFUNGIN	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3
CLEMASTINE	ChEMBL	Phase 4 (approved)	SLC6A2, SLC6A3